Abstract: Compounds for treating a microbial and/or bacterial infection and, particularly, to compounds that are 5-(substitutedphenyl)-7-thioxo-7,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues and their use as anti-microbial or anti-bacterial agents.

Abstract: Compounds for treating a microbial and/or bacterial infection and, particularly, to compounds that are 5-(substitutedphenyl)-7-thioxo-7,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues and their use as anti-microbial or anti-bacterial agents.

Abstract: Compounds for treating a microbial and/or bacterial infection and, particularly, to compounds that are 5-(substituted phenyl)-7-thioxo-7,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues and their use as anti-microbial or anti-bacterial agents.

Abstract: Compounds for treating an inflammatory disease, disorder, or condition and, particularly, to compounds that are 5-(substitutedphenyl)-7-imino-7,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues and their use as anti-inflammatory agents.

Abstract: The liposome encapsulating cysteamine and resveratrol in separate compartments is a liposome having a lipid or lipid bilayer shell and a hydrophilic core. The hydrophilic core contains a hydrophilic antioxidant, which in some embodiments, is cysteamine or pharmaceutically acceptable salts thereof, such as hydrochlorides or bitartrates. The region surrounding the hydrophilic core contains lipids or phospholipids and at least one lipophilic antioxidant, such as resveratrol. The lipophilic contents of the liposome surrounding the hydrophilic core tend to partition from the hydrophilic core and associate with the lipid or lipid bilayer shell. In some embodiments, the liposome composition may be used for the treatment of acute lung injury or acute respiratory distress syndrome, the antioxidants helping to reduce or alleviate inflammation, whether resulting from disease or trauma.

Abstract: Adenosine receptor active compounds including 1,2,3,6,8-pentasubstituted indolizines and methods of using the same for inhibiting adenosine receptor activity are provided. These methods can be used to treat one or more pathological conditions of the central and peripheral nervous systems, such as but not limited to allergies, inflammation, glaucoma, brain ischemia, renal fibrosis, cancer, rheumatoid arthritis, psoriasis fatty liver diseases, stroke, pain, and any combination thereof.

Abstract: Compounds for treating cancer and, particularly, to compounds that are 5-(3-substituted phenyl)-pyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione analogues and their use as anticancer agents.

Abstract: Compounds for treating tuberculosis and, particularly, anti-tubercular compounds that are ethyl 2-substitued-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives and their use as anti-tubercular agents are provided.

Abstract: Compounds for treating cancer and, particularly, to compounds that are 5-(3-substituted phenyl)-pyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione analogues and their use as anticancer agents. The compounds have the structure: wherein: R1 is selected from the group consisting of hydrogen, hydroxy, and benzyloxy; R2 is selected from the group consisting of hydrogen, a C1-C6 straight or branched chain alkoxy, and benzyloxy; R3 is selected from the group consisting of hydrogen and a C1-C6 straight or branched chain alkyl; and R4 is selected from the group consisting of hydrogen and a C1-C6 straight or branched chain alkyl.

Abstract: Compounds for treating tuberculosis and, particularly, antitubercular compounds that are substituted 7-methyl quinoline derivatives and their use as antitubercular agents are provided.

Abstract: Compounds for treating tuberculosis and, particularly, antitubercular compounds that are 1-substituted benzoyl-4-bromopyrrolo[1,2-a]quinoline-3-carboxylate derivatives and their use as antitubercular agents are provided.

Abstract: Compounds for treating an inflammatory disease, disorder, or condition and, particularly, to compounds that are 5-(substitutedphenyl)-7-imino-7,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues and their use as anti-inflammatory agents.

Abstract: Compounds for treating tuberculosis and, particularly, to anti-tubercular compounds that are phenyl quinolin-1-ium bromide derivatives and their use as anti-tubercular agents.

Abstract: Compounds for treating tuberculosis and, particularly, anti-tubercular compounds that are ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives and their use as anti-tubercular agents are provided.

Abstract: The substituted indolizine dicarboxylates are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against tuberculosis mycobacteria. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.

Abstract: Decontamination of water using guar gum (GG) derivatives and applications thereof are provided herein. For water decontamination, guar gum cinnamate (GGCi) is fabricated into nanoparticles having a high surface area that facilitates the removal of water pollutants by adsorption. Owing to its high availability, low cost, slow biodegradability and high sustainability, GG is considered promising as a next generation cost effective green material for water decontamination.

Abstract: Anti-tubercular compounds include trisubstituted indolizines having the following structural formula: wherein R1 is selected from the group consisting of 4-OCH3, 4-Cl, 4-Br, 4-F, 2-NO2, 3,5-CF3, CN, CH3, R2 is COOCH3, COOC2H5, and R3 is H and COOCH3.